Mr. Lynn D. Torbeck - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Mr. Lynn D. Torbeck


Mr. Lynn D. Torbeck is a Pharmtech editorial advisory board (EAB) member

Mr. Lynn D. Torbeck
Principal Statistician
Torbeck & Associates

Lynn D. Torbeck is a consultant specializing in applied statistics and experimental design for pharmaceutical and biopharmaceutical development, quality assurance and control, validation, and production under the CGMPs. Areas of expertise include quality by design, design space, OOS, SQC/SPC, statistical PAT, assay validation, sampling plans, and setting specification criteria. Torbeck has been active in the pharmaceutical industry in statistics, quality, and management since 1975; he has been president of Torbeck and Assoc., Inc. since 1988. He has worked with a wide variety of companies, including pharmaceuticals, biotechnology, fine chemicals, medical devices, and cosmetics. Torbeck is the author of several books on validation and has published a number of journal articles.

Torbeck has been a member of the Editorial Advisory Board of Pharmaceutical Technology since 1999, and was elected to the PDA Scientific Advisory Board (SAB) in 2002 and the USP Statistics Expert Committee for a second five-year term in 2005. He was chair of the PDA’s SAB Out-Of-Specification committee. He won the PDA TRI Excellence in Teaching Award in 1997 and again in 2007. He is also a member of the ASTM E-11, statistics, and E-55, PAT, committees.

Torbeck is a member of the American Statistical Association, PDA, Senior Member of the American Society for Quality, ASQ, ASTM, and is past president of the Chicago Chapter of the American Statistical Association. He is a past Book Reviews Editor for the Journal of Quality Technology, a publication of the American Society for Quality. He holds an AAS degree in Electronics and BS and MS degrees in Statistics with minors in Operations Research and Computer Science.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here